[Survival analysis of 1,742 patients with stage IV non-small cell lung cancer]

Hong Peng, Meili Ma, Baohui Han, Hong Peng, Meili Ma, Baohui Han

Abstract

Background and objective: At present non-small cell lung cancer (NSCLC) is still the leading cause of death induced by cancer. The aim of this study is to investigate the prognostic factors of advanced NSCLC.

Methods: Total 1,742 cases of stage IV NSCLC data from Jan 4, 2000 to Dec 25, 2008 in Shanghai Chest Hospital were collected, confirmed by pathological examinations. Analysis was made to observe the impact of treatment on prognosis in gender, age, smoking history, pathology, classification, clinical TNM stage. Survival rate, survival difference were evaluated by Kaplan-Meire method and Logrank test respectively. The prognosis were analyzed by Cox multivariate regression.

Results: The median survival time of 1,742 patients was 10.0 months (9.5 months-10.5 months). One, two, three, four, and five-year survival rates were 44%, 22%, 13%, 9%, 6% respectively. The median survivals of single or multiple metastasis were 11 months vs 7 months (P < 0.001). Survival time were different in metastasic organs, with the median survival time as follows: lung for about 12 months (11.0 months-12.9 months), bone for 9 months (8.3 months-9.6 months), brain for 8 months (6.8 months-9.1 months), liver, adrenal gland, distant lymph node metastasis for 5 months (3.8 months-6.1 months), and subcutaneous for 3 months (1.7 months-4.3 months). The median survival times of adenocarcinoma (n=1,086, 62%) and squamous cell carcinoma cases (n=305, 17.5%) were 12 months vs 8 months (P < 0.001). The median survival time of chemotherapy and best supportive care were 11 months vs 6 months (P < 0.001); the median survival times of with and without radiotherapy were 11 months vs 9 months (P=0.017).

Conclusions: Gender, age, gross type, pathological type, clinical T stage, N stage, numbers of metastatic organ, smoking history, treatment of advanced non-small cell lung cancer were independent prognostic factors.

Figures

1
1
1, 742例Ⅳ期NSCLC的生存曲线 1, 742 cases of Ⅳ NSCLC survival curve

References

    1. Jemal A, Murray T, Samueh A, et al. Cancer statistics. 2003. CA Cancer J Clin. 2003;53(1):5–26. doi: 10.3322/canjclin.53.1.5.
    1. Janssen-heijnen ML, Smulders S, Lemmens, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non small cell lung cancer. Torax. 2004;59(7):602–607.
    1. Liao ML, Zhou YZ, Ding JA, et al. The study of peri-operative chemotherapy in stage Ⅰ-Ⅲa NSCLC. Nat Med J China. 2003;83(11):962–966. doi: 10.3760/j:issn:0376-2491.2003.11.016.
    2. 廖 美琳, 周 允中, 丁 嘉安, et al. 围手术期化疗在非小细胞肺癌中的应用探讨. 中华医学杂志. 2003;83(11):962–966. doi: 10.3760/j:issn:0376-2491.2003.11.016.
    1. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-smal1 cell lung cancer. J Clin Oncol. 2005;23(28):6829–6837. doi: 10.1200/JCO.2005.01.0793.
    1. Regina S, Rollin J, Bléchet C, et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thoracic Oncol. 2008;3(7):689–697. doi: 10.1097/JTO.0b013e31817c1b21.
    1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cel l lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi: 10.1056/NEJMoa061884.
    1. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase Ⅲ study in advanced non-small cell lung cancer (NSCLC) J Clin Oncol. 2009;27(18s):abstr CR8000. doi: 10.1200/jco.2009.27.18s.cra8000.
    1. Deterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–271. doi: 10.1378/chest.08-0978.
    1. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced nonsmall cell lung cancer: a meta-analysis. Lancet. 1993;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-M.
    1. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954.
    1. Ochs J, Grous JJ, Warner KI, et al. Final survival and safety results for 21 064 non small cell lung cancer patients who received compassionate use geftinib in a US expanded access program (EAP) J Clin Oncol. 2004;22(14S):Abstr 7060.
    1. Nokihara H, Ohe Y, Kawaishi M, et al. A randomized phase Ⅱ study of sequential carboplatin/paclitaxel (CP) and geftinib (G) in chemotherapy naïve patients with advanced non small cell lung cancer:Preliminary results. J Clin Oncol. 2006;24(18s):7096.
    1. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebocontrolled, phase Ⅲb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) afer completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non small cell lung cancer (NSCLC) J Clin Oncol. 2009;27(18S):abstr LBA8002. doi: 10.1200/jco.2009.27.18s.lba8002.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner